Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer

Abstract

As a part of a major study on the pathophysiologic indices for recurrence of human breast cancer, preoperative eosinophil and lymphocyte counts were determined on 419 and 581 primary breast cancer patients, respectively. Patients with lymphocyte counts less than or equal to 1500/mm3 and/or eosinophil counts of less than 55/mm3 had significantly higher risk of recurrent disease than those patients who had normal or high levels of eosinophils and/or lymphocytes. These findings may indicate that the immunologic activities of eosinophils and lymphocytes enhance the patients' ability to respond against disease. Cancer 52:126‐130, 1983.

Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Aid in Colorectal Cancer

“…Neutrophils and lymphocytes play different role in cancer related inflammatory response. Neutrophils are described to be main source of circulating angiogenetic and growth factors, which helps the tumor progression whereas lymphocytes dominate host immune response via cytotoxic cell death and cytokines production that inhibit proliferation of tumor cells (Ownby et al, 1983;Strieter et al, 2006). Although these explanations, the meaning of elevated NLR remains unclear.…”

The Neutrophil to Lymphocyte Ratio has a High Negative Predictive Value for Pathologic Complete Response in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

“…Neutrophils are main sources of circulating angiogenetic and growth factors, which helps the tumor progression whereas lymphocytes dominate host immune response via cytotoxic cell death and cytokines production that inhibit proliferation of tumor cells (Ownby et al, 1983;Strieter et al, 2006). Lymphopenia is an independent prognostic factor for overall and progression-free survival in many cancers (Fogar et al, 2006;Ray-Coquard et al, 2009;Dou X et al, 2013).…”

Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum

“…23,24 Accordingly, also the count of peripheral leukocytes strongly influences BC prognosis. 25 Platelets, eosinophils, neutrophils and monocytes contain high amounts of MMP-9 forms that may be extracellularly released upon activation or during aggregation. [26][27][28] It is worth noting that BC infiltrating lymphocytes showed an increased expression of several MMPs during invasion and metastasis, as well as mononuclear and neutrophilic infiltrates were associated with breast epithelial proliferation.…”

“…[22][23][24] These evidences suggest the role of leukocyte degranulation for the release of MMP in blood, especially in patients affected by breast diseases. 21,25 In this respect, the use of anticoagulants [13][14][15] limits the mobilization of gelatinase-rich granules of human neutrophils, 27 leading to a minimal release of MMP-9 forms in plasma. 15,16 The major differences between plasma and serum involve MMP-9 forms and to a much lesser extent MMP-2, which is considered the constitutive MMP circulating in blood.…”